Latest news with #DynoTherapeutics
Business Wire
14-05-2025
- Business
- Business Wire
Dyno Therapeutics Launches Three Breakthrough Capsid Delivery Vectors for Next-Generation Eye, Muscle and CNS Gene Therapies at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced the launch of three new adeno-associated virus (AAV) capsid gene delivery vectors targeting the eye, musculoskeletal system and central nervous systems (CNS), each with best-in-class potential. Key data from the capsids were presented in a Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and in three oral abstract presentations. 'I'm excited for Dyno to expand our offerings for our gene delivery partners with these new optimized capsids that more efficiently and more specifically deliver therapeutic genes to the eye, muscle and brain,' said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno. 'These new capsids advance the frontiers of gene delivery, bringing Dyno's partners and the field one key step closer to realizing the full potential of genetic medicine to transform patient lives.' Ineffective delivery of therapeutic genes to specific organs and cells in vivo is the most limiting challenge for gene therapy today. Dyno's platform applies advanced AI models trained on data from high-throughput in vivo measurements in animal models to design AAV capsids that are optimized for delivery efficiency, precision targeting, and manufacturability. By sharing these improved gene delivery technologies with partners, Dyno aims to improve the effectiveness of genetic medicines, reducing delivery costs and accelerating the development of optimized therapies that address a wide range of human health challenges via genetic perturbations that address the root cause of each disorder. Each Dyno capsid was optimized and validated for in vivo delivery to cynomolgus monkey (Macaca fascicularis), the most relevant non-human primate (NHP) model for predicting translation potential for human therapy. Dyno's presentations highlighted the optimized performance, translatability, and manufacturability of the Dyno-4z2 capsid for eye delivery, Dyno-3hv capsid for neuromuscular delivery, and Dyno-ahq capsid for CNS delivery: Dyno-4z2 for Eye Delivery The Dyno-4z2 capsid is optimized for delivery to the retina upon intravitreal (IVT) injection and shows exceptional efficiency transducing bipolar cells in the inner nuclear layer (INL), supporting its use in optogenetic ocular gene therapies to restore vision for patients with retinal degeneration: Greater than 40-fold improvement in broad retinal transduction compared to AAV2 at doses of 1e10-1e11 vg/eye in NHP. A 5-fold improvement in transduction of bipolar cells and across the INL in NHP compared to a reference externally engineered capsid, an improvement also observed when both capsids were tested in mice. Easy to administer via IVT injection, enabling broader patient access compared to more invasive subretinal injections. Manufacturable at large scales and compatible with AAV2-based processes. Dyno-3hv for Neuromuscular Delivery Dyno-3hv is the first AAV capsid to demonstrate highly-efficient and enhanced delivery to the multiple tissues affected by neuromuscular disorders, enabling high efficient delivery to heart, skeletal muscle and brain with a single drug product: Transduces 53-90% of skeletal myofibers and multiple regions of the heart and CNS with IV injection at a dose of 4e12 vg/kg in NHPs. Potential for safer IV dosing through liver detargeting, with <10 vg/dg observed in liver in NHP after IV dosing at 4e12vg/kg and low biodistribution to other off-target organs. Easy to administer via IV injection, enabling broader patient access compared to more invasive intracranial and intramuscular injections. Identification of a novel receptor for crossing the blood-brain-barrier (BBB) and demonstration of conserved Dyno-3hv binding to both NHP and human orthologues supports translation for human therapies. Easily manufactured at large scale and compatible with AAV9-based processes. Dyno-ahq for CNS Delivery Dyno-ahq is optimized for widespread and efficient delivery to the brain and throughout the CNS upon IV injection. With enhanced CNS delivery efficiencies compared to prior Dyno capsids, exceptional increases in liver detargeting, and a known mechanism for crossing the BBB that is conserved between NHPs and humans, Dyno-ahq has exceptional utility for delivering gene therapies addressing neurological diseases: Reaches up to 30% of neurons in NHP after crossing the BBB at a dose of 3e13 vg/kg, a 280-fold increase in efficiency compared to the AAV9. Liver detargeting in NHP by greater than 50-fold compared to AAV9, with more neurons being transduced in the brain than hepatocytes in the liver. Easy to administer via IV injection, enabling broader CNS transduction and broader patient access compared to more invasive intraparenchymal and intracisternal injections. Identification of a novel receptor for crossing the BBB and demonstration of conserved Dyno-ahq binding to both NHP and human orthologues supports translation for human therapies. Easily manufactured at large scale and compatible with AAV9-based processes. In addition to unveiling the new capsids, the Dyno Scientific Symposium, 'Leveling up genetic medicine with frontier AI and AAV vectors for CNS, eye, and muscle,' provided updates on Dyno's frontier AI algorithms and strategy to rapidly advance next-generation gene therapies incorporating these capsids into human clinical trials by expanding partnerships with gene therapy developers, towards approval of new treatments in areas of high unmet patient need. Licensing Dyno Capsid Technology Alongside the previously released Dyno-86m (also known as Dyno eCap™ 1) optimized for eye delivery, and Dyno-hc9 (also known as Dyno bCap™ 1) capsid optimized for brain delivery, the Dyno-4z2, Dyno-3hv and Dyno-ahq capsids and additional proprietary platform technologies are available for licensing to Dyno's gene therapy partners. 'By solving the grand challenge of in vivo delivery with optimized capsids, our goal is to enable Dyno's partners to transform patient lives with breakthrough genetic medicines,' says Kelsic. 'With breakthrough new capsids like Dyno-4z2, Dyno-3hv, and Dyno-ahq, we are advancing the frontiers of delivery across therapeutic areas. These innovations reflect the quality and depth of our in vivo data, the power of our AI algorithms for sequence design, and our commitment to helping partners develop exceptional gene therapies that are safe, highly-effective and accessible to patients worldwide.' About Dyno Therapeutics Dyno Therapeutics' mission is to build high-performance genetic technologies that transform patient lives. Dyno is creating better technologies for gene delivery and sequence design to increase 'Genetic Agency'—the capacity for patients to take action and improve their health at a genetic level—enabling individuals to live the life they choose through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including strategic collaborations with leading gene therapy developers Astellas, Roche and Sarepta, and with technology companies including NVIDIA. Visit for more information. Forward-Looking Statements: The capsids described are investigational and intended for future clinical development. References to delivery performance or therapeutic potential are based on preclinical data and do not imply regulatory approval or clinical validation. Licensing is subject to agreement terms.
Yahoo
14-05-2025
- Business
- Yahoo
Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across the gene therapy community to foster collaboration and align efforts towards solving unmet patient needs. The new Dyno Frontiers Program offers therapeutic developers access to Dyno's gene delivery technology and scientific expertise towards demonstrating the transformative therapeutic potential of innovative genetic payloads. These initiatives reinforce Dyno's commitment to enabling genetic agency by empowering patients to take action and improve their health with safe, effective and widely accessible genetic technologies. WATERTOWN, Mass., May 14, 2025--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying AI to enable safe and effective in vivo delivery of genetic medicines, today announced two new initiatives designed to accelerate progress across the gene therapy field: the inaugural Genetic Agency Technology Conference (GATC) and the Dyno Frontiers Program for innovative therapeutic developers. Details were shared during the company's Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. "At Dyno, we believe that building the next generation of therapies will require not just new technical innovation, but also collaboration between many stakeholders and a focused effort to thoroughly solve present bottlenecks," said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno. "These two new initiatives reflect Dyno's commitment to maximizing our positive impact on patients. We achieve this by partnering and by deepening relationships within a community of gene therapy developers, technical experts and patients, along with their families and patient advocates – all united by the common goal of enabling patients to improve their health with safe and effective genetic medicines." The Genetic Agency Technology Conference Dyno's GATC event is scheduled to take place in Boston, Massachusetts on November 11th, 2025. This one-day interactive gathering will convene leaders from across the gene therapy ecosystem—including technical experts, therapeutic developers, patients, their families and patient advocates—to strengthen a community working to develop cutting-edge technologies and drive progress toward solving unmet patient needs. With GATC, Dyno aims to spark collaboration around the shared goal of genetic agency: giving patients the ability to improve their health at a genetic level through access to next‑generation gene technologies that are safe, effective and widely accessible. "When developing a new technology, the most important thing is to make something people want. GATC will bring therapeutic developers working at the frontiers of science and technology together with those who care the most about these transformative treatments: patients, their families and patient advocacy organizations. As we team up to overcome the extraordinary challenges required to develop groundbreaking new medicines, we should also recognize the amazing progress that is being made across fields, and look ahead with optimism to a better future for patients that we can build, when leaders across science, technology, and patient advocacy work together," Kelsic explains. "By bringing the developers and users of these technologies together, GATC will catalyze collaboration, helping uncover the true nature of present challenges, and generating unexpected insights that will accelerate progress to realize the potential of what genetic medicine can deliver for patients." Interested participants can sign up for updates or request an invitation at Further details about the conference will be announced in the coming months. The Dyno Frontiers Program Building on Dyno's successful partnerships with leading gene therapy companies, the Dyno Frontiers Program focuses on assisting select gene therapy developers looking to demonstrate the transformative therapeutic potential of their innovative genetic payloads. The program provides technological and scientific support for developers to initiate non-human primate (NHP) studies with clinic-ready genetic payloads for eye, muscle, or central nervous system indications. Participants in the Frontiers Program will: Gain access to Dyno's leading-edge AAV capsid delivery vectors to demonstrate the in vivo effectiveness of their innovative clinic-ready genetic payloads in eye, muscle, or central nervous system indications. Receive scientific advice from Dyno on capsid selection, NHP study design, vector manufacturing, and performance quantification. Collaborate with Dyno to measure capsid performance across distinct payload modalities. "As genetic technologies advance and diversify, gene therapy developers increasingly need high-performance delivery vectors to realize the therapeutic potential of their innovative payload strategies," Kelsic continued. "We're excited to offer this first-of-its-kind opportunity for innovative gene therapy developers to demonstrate the in vivo effectiveness of their genetic payloads, bringing these transformative drug candidates one critical step closer to the patients who need them most." Eligible therapeutic developers seeking to demonstrate the therapeutic potential of their innovative clinic-ready genetic payloads are invited to participate at About Dyno Therapeutics Dyno Therapeutics' mission is to build high-performance genetic technologies that transform patient lives. Dyno is creating better technologies for gene delivery and sequence design to increase "Genetic Agency"—the capacity for patients to take action and improve their health at a genetic level—enabling individuals to live the life they choose through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including strategic collaborations with leading gene therapy developers Astellas, Roche and Sarepta, and with technology companies including NVIDIA. Visit for more information. Note: The Dyno Frontiers Program is a research initiative and does not imply clinical validation, endorsement, or regulatory approval. View source version on Contacts Media Contact:Thermal for Dyno Therapeuticsdynotx@ Sign in to access your portfolio
Business Wire
14-05-2025
- Business
- Business Wire
Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dyno Therapeutics, Inc., a genetic technologies company applying AI to enable safe and effective in vivo delivery of genetic medicines, today announced two new initiatives designed to accelerate progress across the gene therapy field: the inaugural Genetic Agency Technology Conference (GATC) and the Dyno Frontiers Program for innovative therapeutic developers. Details were shared during the company's Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. 'At Dyno, we believe that building the next generation of therapies will require not just new technical innovation, but also collaboration between many stakeholders and a focused effort to thoroughly solve present bottlenecks,' said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno. 'These two new initiatives reflect Dyno's commitment to maximizing our positive impact on patients. We achieve this by partnering and by deepening relationships within a community of gene therapy developers, technical experts and patients, along with their families and patient advocates – all united by the common goal of enabling patients to improve their health with safe and effective genetic medicines.' The Genetic Agency Technology Conference Dyno's GATC event is scheduled to take place in Boston, Massachusetts on November 11th, 2025. This one-day interactive gathering will convene leaders from across the gene therapy ecosystem—including technical experts, therapeutic developers, patients, their families and patient advocates—to strengthen a community working to develop cutting-edge technologies and drive progress toward solving unmet patient needs. With GATC, Dyno aims to spark collaboration around the shared goal of genetic agency: giving patients the ability to improve their health at a genetic level through access to next‑generation gene technologies that are safe, effective and widely accessible. 'When developing a new technology, the most important thing is to make something people want. GATC will bring therapeutic developers working at the frontiers of science and technology together with those who care the most about these transformative treatments: patients, their families and patient advocacy organizations. As we team up to overcome the extraordinary challenges required to develop groundbreaking new medicines, we should also recognize the amazing progress that is being made across fields, and look ahead with optimism to a better future for patients that we can build, when leaders across science, technology, and patient advocacy work together,' Kelsic explains. 'By bringing the developers and users of these technologies together, GATC will catalyze collaboration, helping uncover the true nature of present challenges, and generating unexpected insights that will accelerate progress to realize the potential of what genetic medicine can deliver for patients.' Interested participants can sign up for updates or request an invitation at Further details about the conference will be announced in the coming months. The Dyno Frontiers Program Building on Dyno's successful partnerships with leading gene therapy companies, the Dyno Frontiers Program focuses on assisting select gene therapy developers looking to demonstrate the transformative therapeutic potential of their innovative genetic payloads. The program provides technological and scientific support for developers to initiate non-human primate (NHP) studies with clinic-ready genetic payloads for eye, muscle, or central nervous system indications. Participants in the Frontiers Program will: Gain access to Dyno's leading-edge AAV capsid delivery vectors to demonstrate the in vivo effectiveness of their innovative clinic-ready genetic payloads in eye, muscle, or central nervous system indications. Receive scientific advice from Dyno on capsid selection, NHP study design, vector manufacturing, and performance quantification. Collaborate with Dyno to measure capsid performance across distinct payload modalities. 'As genetic technologies advance and diversify, gene therapy developers increasingly need high-performance delivery vectors to realize the therapeutic potential of their innovative payload strategies,' Kelsic continued. 'We're excited to offer this first-of-its-kind opportunity for innovative gene therapy developers to demonstrate the in vivo effectiveness of their genetic payloads, bringing these transformative drug candidates one critical step closer to the patients who need them most.' Eligible therapeutic developers seeking to demonstrate the therapeutic potential of their innovative clinic-ready genetic payloads are invited to participate at About Dyno Therapeutics Dyno Therapeutics' mission is to build high-performance genetic technologies that transform patient lives. Dyno is creating better technologies for gene delivery and sequence design to increase 'Genetic Agency'—the capacity for patients to take action and improve their health at a genetic level—enabling individuals to live the life they choose through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including strategic collaborations with leading gene therapy developers Astellas, Roche and Sarepta, and with technology companies including NVIDIA. Visit for more information. Note: The Dyno Frontiers Program is a research initiative and does not imply clinical validation, endorsement, or regulatory approval.
Business Wire
29-04-2025
- Business
- Business Wire
Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that it will present a broad set of data related to the design of novel capsids targeting the eye, brain, and neuromuscular system using frontier AI during a Scientific Symposium and three oral presentations at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The data will highlight Dyno's leadership in solving the biggest challenge limiting the viability and accessibility of gene therapy: safely and efficiently delivering therapeutic genetic payloads to target cells in vivo. To solve this challenge, Dyno applies AI and high-throughput in vivo data collection to design AAV capsids that are optimized for efficiency, precision targeting, and manufacturability. By extending these high-performance design capabilities and delivery technologies to therapeutic developers, Dyno aims to advance the effectiveness of next-generation gene therapies, making them applicable for a wide range of human diseases. In the Scientific Symposium, Dyno Cofounder and CEO, Eric Kelsic, Ph.D., will detail three new AAV capsids with improved performance for targeting the central nervous system (CNS), eye, and neuromuscular system, as well as updates on the frontier AI models behind their discovery. Dr. Kelsic will also share how Dyno intends to rapidly progress these next-generation gene therapies into the clinic, add new treatments in areas of high unmet need, and improve access to transformative medicines by expanding partnerships with gene therapy developers. Scientific Symposium Title: Dyno Therapeutics: Leveling up genetic medicine with frontier AI and AAV vectors for CNS, eye, and muscle Presenter: Eric Kelsic, Ph.D., Cofounder & CEO Date and Time: Wednesday, May 14th from 12:15 – 1:15 PM CT Location: Room 391-392 In addition to the Symposium, three research abstracts selected for oral presentation will present data on Dyno's progress enabling gene delivery for CNS, eye and neuromuscular indications: Oral Presentations Title: Widespread CNS Delivery With Best-In-Class Liver Detargeting Following Intravenous Injection of a Novel AAV Presenter: Mugdha Deshpande, Ph.D. Session: AAV Gene Transfer (A): Crossing the Blood-Brain Barrier Date and Time: Wednesday, May 14, 2025, 1:30 PM - 1:45 PM CT Location: New Orleans Theater C Abstract: 2220 Title: Selective Improvement in Retinal Bipolar Cell Targeting with Intravitreal Injection of a Novel AAV Capsid in Mouse and NHP Presenter: Amanda Miles, Ph.D. Session: AAV Gene Transfer (B): Ocular, Neurological & Immune Cell Systems Date and Time: Friday, May 16, 2025, 2:45 PM - 3:00 PM CT Location: New Orleans Theater A Abstract: 2175 Title: A Novel Neuromuscular AAV Capsid Combines Efficient Systemic Muscle and CNS Delivery with Liver Detargeting in NHP Presenter: Megan Cramer, Ph.D. Session: AAV Gene Transfer (C): Antibody Evasion, Cardiac & Neuromuscular Targets Date and Time: Saturday, May 17, 2025, 11:45 AM - 12:00 PM CT Location: New Orleans Theater A Abstract: 2208 More details about the Scientific Symposium and oral presentations are available on the ASGCT meeting website. About Dyno Therapeutics Dyno Therapeutics is building high-performance genetic technologies that transform patient health by overcoming the in vivo gene delivery challenge for therapeutic developers. Dyno's platform integrates frontier AI with high-throughput experimentation to accelerate the optimization of AAV capsids that significantly outperform existing gene delivery vectors. Just as exponential breakthroughs in computer chip technology powered the AI revolution, Dyno's versatile platform leverages foundational advances from in vivo multiplexing technologies and high-performance computing to address therapeutic grand challenges. Dyno is partnering with leading gene therapy developers, including Astellas, Roche, and Sarepta, and with technology companies including NVIDIA. Visit for additional information.
